Dr. Senna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Staniford St
Boston, MA 02114Phone+1 617-726-2914
Summary
- Dr. Maryanne Senna is a Dermatologist based in Boston, MA, with impressive experience in general dermatology, alopecia, pediatric dermatology, and complex medical dermatology. Her medical education was completed at Tufts University School of Medicine, pursued an internship in Internal Medicine at Beth Israel Deaconess Medical Center, and a residency in Dermatology at the University of Massachusetts. She is also a published author, having contributed to research articles in multiple esteemed journals such as JAMA Dermatology and the Journal of the American Academy of Dermatology. She is further engaged in the field of Dermatology as she is involved in the design and validation of a new assessment tool for Lichen Planopilaris in clinical trials.
Education & Training
- UMass Chan Medical SchoolResidency, Dermatology, 2010 - 2013
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2009 - 2010
- Tufts University School of MedicineClass of 2009
Certifications & Licensure
- NH State Medical License 2024 - 2026
- MA State Medical License 2013 - 2025
- American Board of Dermatology Dermatology
Clinical Trials
- Design and Validation of a New Assessment Tool for Lichen Planopilaris Start of enrollment: 2017 Feb 10
Publications & Presentations
PubMed
- 5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-mat...Li-Chi Chen, Tina Yi Jin Hsieh, Maryanne M Senna
Journal of the American Academy of Dermatology. 2025-02-01 - Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.Brett King, Manabu Ohyama, Maryanne Senna, Jerry Shapiro, Yves Dutronc
Journal of the American Academy of Dermatology. 2025-02-01 - Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysi...Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair
Journal of the American Academy of Dermatology. 2025-02-01
Press Mentions
- Topical JAK Inhibitor Shows Promise for Frontal Fibrosing AlopeciaOctober 2nd, 2024
- Another Win for a JAK Inhibitor in Alopecia AreataMarch 19th, 2023
- Male Alopecia Agents Ranked by Efficacy in Meta-AnalysisFebruary 11th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: